ABN.AS: $40.75 ▲ 0.30 (0.74%)DSFIR.AS: $99.66 ▼ -0.99 (-0.98%)GMAB.CO: $2,487.00 ▲ 42.00 (1.72%)REP.MC: $29.21 ▼ -0.31 (-1.05%)SOON.SW: $267.80 ▲ 3.20 (1.21%)CRWD: $263.07 ▼ -11.97 (-4.35%)HPE: $70.13 ▼ -3.33 (-4.53%)AMD: $590.04 ▼ -18.06 (-2.97%)DELL: $574.99 ▼ -11.07 (-1.89%)PANW: $399.75 ▼ -19.03 (-4.54%)MRNA: $214.23 ▼ -10.77 (-4.79%)AAPL: $339.52 ▲ 2.88 (0.86%)AMZN: $259.82 ▼ -2.61 (-0.99%)MSFT: $539.81 ▲ 4.74 (0.89%)NVDA: $226.42 ▼ -2.86 (-1.25%)CIEN: $403.29 ▼ -46.48 (-10.34%)DDOG: $287.72 ▼ -5.54 (-1.89%)SNPS: $503.07 ▼ -6.92 (-1.36%)CAP.PA: $115.35 ▲ 0.30 (0.26%)TSCO.L: $511.00 ▲ 7.20 (1.43%)WKL.AS: $77.16 ▲ 2.16 (2.88%)

Company Details

Qualigen Therapeutics, Inc.

QLGN - NASDAQ

Identifiants & Marche

Ticker QLGN
ISIN US74754R2022
CIK 0001460702
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.